Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Merck (MRK) Buys Rights to Mid-Stage Prostate Cancer Candidate
12:24pm, Thursday, 14'th Jul 2022
Merck (MRK) is set to make an upfront payment of $290 million to Orion for co-development and co-commercialization rights to ODM-208.
Merck (MRK) Gains As Market Dips: What You Should Know
09:45pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
In the latest trading session, Merck (MRK) closed at $93.77, marking a +0.18% move from the previous day.
Here's Why You Should Retain Thermo Fisher (TMO) Stock Now
04:18pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Investors are optimistic about Thermo Fisher's (TMO) strong end market growth and noteworthy acquisitions.
Rhythm (RYTM) Surges on Upbeat Data on Lead Product Candidate
04:15pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Rhythm Pharmaceuticals (RYTM) reports favorable data from a mid-stage study evaluating the efficacy of setmelanotide, its MC4R agonist, for treating hypothalamic obesity.
Quest Diagnostics (DGX) to Report Q2 Earnings: What's In Store?
04:00pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Quest Diagnostics (DGX) second-quarter 2022 results will likely have gained from an ongoing rebound in the base business.
Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study
02:59pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.
CVS Health (CVS) Pharmacy Claims Volume Grows, Margin Woes Stay
02:34pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
CVS Health's (CVS) investments in constructing affordable housing units in Denver, Fresno, Nashville and San Antonio seem encouraging.
Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug
02:32pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.
Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises
02:29pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).
7 High-Yield Retirement Dream Blue-Chips For This Recession
01:45pm, Wednesday, 13'th Jul 2022 Seeking Alpha
On an annualized inflation-adjusted basis the stock market just had its worst first half since 1872. Read more to see 7 high-yield stocks for retirement.
3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health
01:31pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Merck (MRK), Bayer (BAYRY) and Jazz Pharmaceuticals (JAZZ) are three large drugmakers that are good stocks to buy.
The Zacks Analyst Blog Highlights Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals
11:37am, Wednesday, 13'th Jul 2022 Zacks Investment Research
Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals are part of Zacks top Analyst Blog.
6 Dow Stocks to Buy on the Dip
10:53am, Wednesday, 13'th Jul 2022
These 6 Dow stocks to buy on the dip might produce excellent returns for the long-term investor. They have low valuations, good earnings growth, and high dividend yields.
3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health
10:45am, Wednesday, 13'th Jul 2022
Merck (MRK), Bayer (BAYRY) and Jazz Pharmaceuticals (JAZZ) are three large drugmakers that are good stocks to buy.
Merck to pay Orion $290 million upfront to develop, commercialize prostate cancer treatment
06:11am, Wednesday, 13'th Jul 2022
Merck & Co. Inc. said Wednesday it will make a $290 million upfront payment to Orion Corp. as part of an agreement to develop and commercialize Orion's prostate cancer treatment ODM-208. Merck said th
